Therefore, tumor cells retain a significantly higher LDH expression level and overall glycolytic program compared with activated CD8+ T cells, creating a therapeutic opportunity for preferential targeting of this enzyme in tumor cells over immune cells. Here, CD8A is linked to neoplasm.